All have seen their factor activity levels climb from 1 or 2 percent well into the double digits; short of normal, but still considered a big improvement. At those levels, patients do not experience spontaneous bleeds, and most injuries are not a problem, either. As of Nov. 30, the patients had all but eliminated the use of synthetic clotting factor, for a collective estimated savings approaching $2 million.